AKT1 and acute respiratory distress syndrome: Eriodictyol alleviates LPS/D-GalN-induced ALI by activating the PI3K/AKT pathway, reducing oxidative stress and apoptosis [14]; it also improves non-alcoholic fatty liver disease by downregulating UBA52 to promote autophagy and activating the Nrf2/HO-1 pathway to inhibit oxidative stress [15].